Trials / Unknown
UnknownNCT04560894
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
SCT-I10A in Combination With SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (HCC): A Multicenter, Randomized, Open-label,Phase 2/3 Trial
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 405 (actual)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination with SCT510 in patients with HCC who have not received prior systemic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCT-I10A | Participants receive SCT-I10A intravenously，200mg，d1，Q3w |
| DRUG | SCT510 | Participants receive SCT510 intravenously，15mg/kg，d1，Q3w |
| DRUG | Sorafenib 200mg | Participants receive sorafenib orally，400mg bid |
Timeline
- Start date
- 2020-11-11
- Primary completion
- 2024-04-01
- Completion
- 2024-09-01
- First posted
- 2020-09-23
- Last updated
- 2024-02-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04560894. Inclusion in this directory is not an endorsement.